BALPHARMA2023-10-012023-12-31 BALPHARMA2023-10-012023-12-31 BALPHARMA2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member BALPHARMA2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member BALPHARMA2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524824 BALPHARMA NOTLISTED Bal Pharma Limited Equity 2023-04-01 2024-03-31 2024-02-12 2024-01-25 INR Lakhs Third quarter 16:45:00 18:00:00 2024-02-12 2024-02-12 Not applicable Single segment PHARMACEUTICLES 2023-10-01 2023-12-31 Unaudited Standalone 814946000.00 2571000.00 817517000.00 379169000.00 16676000.00 62724000.00 141705000.00 36607000.00 25510000.00 138385000.00 800776000.00 16741000.00 0.00 16741000.00 6551000.00 -2382000.00 4169000.00 0.00 12572000.00 0.00 0.00 0.00 0.00 12572000.00 0.00 12572000.00 0.00 0.00 158043000.00 10 0.80 0.80 0.00 0.00 0.80 0.80 NOTES : 1. The above Unaudited standalone financial results of the Company have been reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 12th February 2024. 2. The standalone financial results have been prepared in accordance with the Compannies ( Indian accounting standdard rules ) 2015, IND AS prescribed under Section 133 of the Companies act 2013 read with rules issued thereunder and other recognised accounting practises and policies to the extent applicable. 3. The Company has outstanding recoverability of Rs.897.97 lakhs and Rs.152.74 lakhs from its subsidiaries i.e Lifezen Healthcare Pvt Ltd and Balance Clinics LLP. The said subsidiaries have incurred losses and have negative networth. However the management is confident that with the infusion of additional funds , introduction of new products and renewed marketinng , the Company can be revived and amounts recovered. 4. The Company has not received any intimation or information with regards to vendors registration as a Micro, small and medium enterprises. Accordingly , the entire dues to the vendors has been clasified as payable to other then MSME. 5. The Company has filed application with NCLT for merger of Golden Drugs Pvt Ltd , a wholly owned subsidiary of the Company. 6. The Company has made the allotment of 1,14,500 equity shares ro the eligible employees of the Company who has opted for the exerccise of stock options vested on them. 3,68,000 stock options are still available for vesting during the tenure of the scheme. 7.Previous period figures has been regrouped/rearranged wherever considered necessary to confirm to the period presentation. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 2439603000.00 11177000.00 2450780000.00 1296760000.00 64660000.00 18291000.00 415521000.00 111176000.00 66888000.00 423118000.00 2396414000.00 54366000.00 0.00 54366000.00 21810000.00 -7983000.00 13827000.00 0.00 40539000.00 0.00 0.00 0.00 0.00 40539000.00 0.00 40539000.00 0.00 0.00 158043000.00 10 2.57 2.58 0.00 0.00 2.57 2.58 Other Expenses 138385000.00 Other Expenses 423118000.00